Harvard Drug Continues Expansion With Watson’s Rugby OTC Business

Watson Pharmaceuticals sells OTC business Rugby Laboratories to Harvard Drug Group, which operates Major Pharmaceuticals manufacturing. Watson divests a business that accounted for a small part of the private label OTC market, but keeps its pending ANDAs for guaifenesin expectorants and its smoking-cessation generics.

Harvard Drug Group LLC adds Watson Pharmaceuticals Inc.’sRugby Laboratories Inc.OTC business to its expanding lineup of properties in a $117 million deal announced Oct. 29.

More from United States

More from North America